Pfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company's data shows

  • 📰 CNBC
  • ⏱ Reading Time:
  • 30 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 72%

South Africa News News

South Africa South Africa Latest News,South Africa South Africa Headlines

Pfizer said it will submit an application to the Food and Drug Administration for the RSV vaccine's approval by the end of 2022.

Data shows Pfizer's RSV vaccine given to pregnant mothers as a single dose in the late second or third trimester is effective at protecting newborns, the company said.

RSV is a common respiratory virus that generally causes mild cold-like symptoms, but it can be dangerous for infants younger than 6 months. Pfizer said it will submit an application to the Food and Drug Administration for the vaccine's approval by the end of 2022. The company said it will also submit the results for peer review.

The vaccine was well tolerated with no safety concerns for the mothers or their newborns, according to Pfizer. The mothers were monitored for six months after delivery for any safety concerns, while the babies were followed for at least a year.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Let’s hope this tweet can be used as evidence against you in a court of law

Wouldn't trust any pharma study. They test for desired outcome. They don't test for long term side effects.

Just to let us know right? Yeah....sure

In a recent study 2 out of 3 mice 🐁 died, but your baby is good. They promise!

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in ZA

South Africa South Africa Latest News, South Africa South Africa Headlines